Let’s start up with the current stock price of Catabasis Pharmaceuticals Inc. (CATB), which is $2.71 to be very precise. The Stock rose vividly during the last session to $2.78 after opening rate of $2.39 while the lowest price it went was recorded $2.39 before closing at $2.36.
Recently in News on November 12, 2020, Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update. — Cash and Cash Equivalents Totaled $52.9 Million as of September 30, 2020 –. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Catabasis Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.78 on 01/14/21, with the lowest value was $2.12 for the same time period, recorded on 01/04/21.
Catabasis Pharmaceuticals Inc. (CATB) full year performance was -60.09%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Catabasis Pharmaceuticals Inc. shares are logging -68.45% during the 52-week period from high price, and 116.80% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.25 and $8.59.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2084970 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Catabasis Pharmaceuticals Inc. (CATB) recorded performance in the market was 26.64%, having the revenues showcasing -56.78% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 56.26M, as it employees total of 27 workers.
Catabasis Pharmaceuticals Inc. (CATB) in the eye of market guru’s
During the last month, 0 analysts gave the Catabasis Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 3 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 3.90, with a change in the price was noted -4.84. In a similar fashion, Catabasis Pharmaceuticals Inc. posted a movement of -64.11% for the period of last 100 days, recording 3,459,353 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CATB is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Catabasis Pharmaceuticals Inc. (CATB): Stocks Technical analysis and Trends
Raw Stochastic average of Catabasis Pharmaceuticals Inc. in the period of last 50 days is set at 72.73%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 90.91%. In the last 20 days, the company’s Stochastic %K was 77.22% and its Stochastic %D was recorded 80.54%.
If we look into the earlier routines of Catabasis Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 26.64%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -58.37%, alongside a downfall of -60.09% for the period of the last 12 months. The shares increased approximately by 11.07% in the 7-day charts and went down by 32.20% in the period of the last 30 days. Common stock shares were lifted by -56.78% during last recorded quarter.